REGN Regeneron Pharmaceuticals, Inc.

15,508

$823.81

$15.22

(1.88%)

Today

Watchers	15,508
52-Wk Low	$668.00
52-Wk High	$853.97

Market Cap	$102.59B
Volume (M)	10.00
52-Wk High	$853.97
52-Wk Low	$668.00

Fundamentals

Regeneron to Host Investor Call and Webcast on December 14, 2023 to Provide Updates Across Its Hematology PortfolioGlobe Newswire • 1 day ago

TARRYTOWN, N.Y., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will host a conference call and simultaneous webcast to provide an update on the company's...

Share to Feed

Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Rating Reaffirmed by Truist FinancialZolmax • 1 day ago

Regeneron Pharmaceuticals (NASDAQ:REGN Get Free Report)s stock had its buy rating reaffirmed by investment analysts at Truist Financial in a note issued to investors on...

Regeneron Pharmaceuticals, Inc. (REGN) Piper Sandler 35th Annual Healthcare Conference (Transcript)SeekingAlpha • 3 days ago

Regeneron Pharmaceuticals, Inc. (REGN) Piper Sandler 35th Annual Healthcare Conference (Transcript...

Dupixent (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious DiseaseGlobe Newswire • 4 days ago

NOTUS trial met its primary endpoint with overwhelming efficacy, showing Dupixent significantly reduced exacerbations by 34% compared to placebo in patients with moderate-to-severe COPD with evidence...

Sanofi/Regeneron's Blockbuster Prescription Drug Dupixent Shows Additional Promise In Chronic Lung DisorderBenzinga • 4 days ago

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) announced the second Dupixent (dupilumab) Phase 3 chronic obstructive pulmonary disease (COPD) trial (NOTUS) showed that...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Position Raised by Profund Advisors LLCTicker Report • 12 days ago

Profund Advisors LLC raised its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN Free Report) by 8.9% in the second quarter, according to its most recent 13F filing with the...

Quadrant Capital Group LLC Reduces Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Ticker Report • 13 days ago

Quadrant Capital Group LLC lessened its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN Free Report) by 4.7% during the 2nd quarter, according to its most recent filing...

How Is The Market Feeling About Regeneron Pharmaceuticals?Benzinga • 15 days ago